Hoth Therapeutics Inks Research Pact For Critical Studies Of HT-006 Antibiotic

Hoth Therapeutics Inc HOTH has entered into a Research Agreement with the University of Cincinnati Research Institute to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan.

  • HT-006 is under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia, cystic fibrosis, chronic obstructive pulmonary disease, and ventilator-associated pneumonia.
  • Hoth previously licensed the HT-006 technology for commercial evaluation from the Walter Reed Army Institute of Research.
  • The research plan includes critical antimicrobial in vitro characterization studies for HT-006 in alignment with the FDA's program for "antibacterial therapies.
  • The company says that this streamlined program allows for nonclinical animal studies to reduce clinical studies required for approval.
  • Price Action: HOTH gained 3.3% at $2.19 in market trading hours on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareContractsFDAGeneralantibiotics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!